TP53 and hepatocellular carcinoma: To examine the therapeutic effect, adult zebrafish with HCC (Tg(fabp10a:HBx,p53−) at 11.3 months and Tg(fabp10a:Src,p53−) at 8.7 months) were retro-orbitally injected with 419S1, 420S1, and Sorafenib at concentrations of 15, 30, and 30 μg/g, respectively.